Results 81 to 90 of about 55,457 (267)

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Pre-Clinical Investigation of Liquid Paclitaxel for Local Drug Delivery: A Pilot Study

Pharmaceuticals, 2020
The purpose of this pilot study was to investigate the feasibility of a perfusion catheter to deliver liquid paclitaxel into arterial segments. A clinically relevant rabbit ilio-femoral injury model was utilized to determine the impact of liquid ...
Claire V. Cawthon, Kathryn Cooper, Clifton Huett, Alyssa Lloret, Estefanny Villar-Matamoros, Lauren Stokes, Uwe Christians, Michele Schuler, Saami K. Yazdani   +8 more
doaj   +1 more source

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer [PDF]

, 2017
Weekly administration of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has been shown to be a safe and effective treatment for metastatic breast cancer (MBC) in clinical studies.
Nakayama, Takahiro, Yamauchi, Hideko, Junichiro Watanabe, Masuda, Norikazu, Hitoshi Arioka, Takanori Ishida, Inoue, Kenichi, Takao, Shintaro, Toyama, Tatsuya, Tokuda, Yutaka, Hiroshi Ishiguro, Norikazu Masuda, Yutaka Tokuda, Nobuaki Sato, Masahiro Kashiwaba, Tatsuya Toyama, Sato, Nobuaki, Ishiguro, Hiroshi, Saeki, Toshiaki, Yamada, Kimito, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Tamura, Kenji, Saito, Mitsue, Fujiwara, Yasuhiro, Kenji Tamura, Arioka, Hitoshi, Toshiaki Saeki, Hideko Yamauchi, Aogi, Kenjiro, Kashiwaba, Masahiro, Shintaro Takao, Naohito Yamamoto, Ishida, Takanori, Kimito Yamada, Watanabe, Junichiro, Iwata, Hiroji, Takahiro Nakayama, Kenjiro Aogi, Ohno, Shinji, Mitsue Saito, Yasuhiro Fujiwara, Yamamoto, Naohito   +43 more
core   +1 more source

Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

Advanced NanoBiomed Research, EarlyView.
Redox responsive mesoporous silica nanoparticles (MSNs) were engineered to deliver gemcitabine (Gem) and cisplatin (cisPt) at defined ratios to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Optimized Gem MSNs and Gem cisPt MSNs enhanced cytotoxicity in murine and human Gem resistant models, with select formulations inducing ...
Tamanna Binte Huq, Sudip Kumar Dam, Doaha Awad, Punnya Anil Kumar Jeeja, Farzana Ferdous, Juan L. Vivero‐Escoto   +5 more
wiley   +1 more source

Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma

, 2016
Introducción: Recientemente, nuevos agentes quimioterapéuticos como nab-paclitaxel y gemcitabina han demostrado un beneficio en la supervivencia en comparación con la gemcitabina sola en el cáncer de páncreas metastásico.
Malavé, Hidalgo, Belpo, B., Vicente, Y, Diaz, Fabra,, Quijano, Y., Caruso, Ferri,, Plaza Hernández, José Carlos   +6 more
core   +1 more source

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer

OncoTargets and Therapy, 2014
Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival.
Al-Hajeili,Marwan, Azmi,Asfar, Choi,Minsig   +2 more
openaire   +4 more sources

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

, 2018
BACKGROUND Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes.
Rugo, H. S., Hegg, R., Husain, A., Schneeweiss, A., Wright, G. Shaw, Henschel, V., Im, S. -A., Schmid, P., Adams, S., Chui, S. Y., Loi, S., Funke, R., Emens, L. A., Dieras, V., Iwata, H., Barrios, C. H., Winer, E. P., Molinero, L.   +17 more
core   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

, 2013
Design: Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (
Jodrell, D. I., Neesse, A., Tuveson, D. A., Frese, K. K., Chan, D. S., Richards, F. M., Bapiro, T. E., Ellenrieder, V., Howat, W. J.   +8 more
core   +1 more source